Skip to search formSkip to main contentSkip to account menu

galeterone

Known as: Androsta-5,16-dien-3-ol, 17-(1h-benzimidazol-1-yl)-, (3beta)-, Specific Androgen Receptor Modulator/CYP17 Lyase Inhibitor TOK-001 
An orally bioavailable small-molecule androgen receptor modulator and CYP17 lyase inhibitor with potential antiandrogen activity. Galeterone exhibits… 
National Institutes of Health

Related topics

Related topics

2 relations
NCIt Antineoplastic Agent Terminology

Narrower (1)

TOK-001

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Synthesis of new steroidal quinolines with antitumor properties
2017
2017
The fluorescent two-hybrid assay for live-cell profiling of androgen receptor modulators
2016
2016
The Ongoing Challenges of Targeting the Androgen Receptor.
2015
2015
Androgen receptor modulation optimized for response: Splice variant (ARMOR3-SV)–Randomized, open-label, multicenter, controlled study of galeterone vs enzalutamide in men with metastatic castration…
TPS5069 Background: mCRPC patients with tumors expressing the androgen receptor (AR) splice variant-7 (AR-V7), a constitutively… 
2015
2015
Androgen Receptor Modulation Optimized for Response in Splice Variant (ARMOR3-SV): Randomized, open-label, multicenter, controlled study of galeterone versus enzalutamide (enz) in men expressing AR…
259 Background: Recent data showed that mCRPC patients (pts) with the androgen receptor (AR) SV AR-V7, a truncated form of the AR… 
2014
2014
Galeterone in men with CRPC: Results in four distinct patient populations from the ARMOR2 study.
5029 Background: Galeterone is a 1st in class oral small molecule that disrupts androgen receptor (AR) signaling via multi… 
Review
2014
Review
2014
The Evolution of Prostate Cancer Therapy: Targeting the Androgen Receptor
Prostate cancer treatment has evolvedthrough the varying eras of therapy fromone of predominantly hormonal agentswithout much… 
2013
2013
Differential effects of galeterone, abiraterone, orteronel, and ketoconazole on CYP17 and steroidogenesis.
184 Background: Because CYP17 has a central role in converting progestogens to androgens, inhibitors have been developed to treat… 
2013
2013
Comparison of the pharmacokinetics (PK) of galeterone novel oral formulations.
e16075 Background: Galeterone (gal) is an orally available steroid analog for the treatment of castration resistant prostate… 
2012
2012
Phase I clinical trial of galeterone (TOK-001), a multifunctional antiandrogen and CYP17 inhibitor in castration resistant prostate cancer (CRPC).
4665 Background: Galeterone is an oral steroid analog that suppresses prostate cancer growth by inhibiting CYP17, blocking… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)